CINANSERIN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H24N2OS
Molecular Weight	340.482
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)CCCSC1=C(NC(=O)\C=C\C2=CC=CC=C2)C=CC=C1

InChI

InChIKey=RSUVYMGADVXGOU-BUHFOSPRSA-N

InChI=1S/C20H24N2OS/c1-22(2)15-8-16-24-19-12-7-6-11-18(19)21-20(23)14-13-17-9-4-3-5-10-17/h3-7,9-14H,8,15-16H2,1-2H3,(H,21,23)/b14-13+

HIDE SMILES / InChI

Molecular Formula	C20H24N2OS
Molecular Weight	340.482
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14248340 | https://www.ncbi.nlm.nih.gov/pubmed/23523219

Cinanserin is a 5-hydroxytryptamine receptor antagonist; it shows a low afﬁnity to 5-HT2b binding sites and a 4-to 10-fold lower afﬁnity to 5-HT2c receptor binding sites than for 5-HT2a sites. Nevertheless, at concentrations normally used 5-HT2c receptor blocking effects are still likely. Experiments on animal have shown that intravenous administration of cinanserin significantly reduces systemic burn edema and leukocyte-endothelial interactions.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serotonin 2 receptors; 5-HT2a & 5-HT2c 7 Target ID: CHEMBL2096662 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14248340	Antagonist 2778

Conditions

Condition	Modality	Targets	Highest Phase	Product
Unknown 2578

PubMed

Title	Date	PubMed
Differentiaton of neuropharmacological actions of apomorphine and d-amphetamine.	1976 Dec	139615
p,p'-DDT-induced myoclonus in mice: the effect of enhanced 5-HT neurotransmission.	1985 Feb	2986413
Cocaine-induced convulsions: pharmacological antagonism at serotonergic, muscarinic and sigma receptors.	1997 Feb	9085399
The role of serotonin(2) receptors in mediating cocaine-induced convulsions.	2000 Apr	10764922
Molecular serotonergic mechanisms appear to mediate genetic sensitivity to cocaine-induced convulsions.	2000 Apr 28	10773209

Patents

Sample Use Guides

In Vivo Use Guide

in rats: bolus (5 mg/kg body weight)

Route of Administration: Intravenous

In Vitro Use Guide

Binding of both cinanserin and its hydrochloride to bacterially expressed 3C-like proteinase (3CLpro) of syndrome-associated coronavirus (SARS-CoV) and the related human coronavirus 229E (HCoV-229E) was demonstrated by surface plasmon resonance technology. The antiviral activity of cinanserin was further evaluated in tissue culture assays, namely, a replicon system based on HCoV-229E and quantitative test assays with infectious SARS-CoV and HCoV-229E. The level of virus RNA and infectious particles was reduced by up to 4 log units, with IC50 values ranging from 19 to 34 microM.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:13:38 GMT 2023` Edited by `admin` on `Fri Dec 15 16:13:38 GMT 2023`
Record UNII	KI6J9OY7A3
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CINANSERIN

Official Name

English

cinanserin [INN]

Common Name

English

2-PROPENAMIDE, N-(2-((3-(DIMETHYLAMINO)PROPYL)THIO)PHENYL)-3-PHENYL-

Systematic Name

English

2'-((3-(DIMETHYLAMINO)PROPYL)THIO)CINNAMANILIDE

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C66885